These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 6368517)
21. Efficacy of cefminox compared with amoxicillin/clavulanic acid as a single dose for the prevention of intra-abdominal sepsis in mice intraperitoneally infected with different strains of Escherichia coli and one strain of Bacteroides fragilis. Huelves L; Gracia M; Del Prado G; Rodríguez-Cerrato V; Martínez-Marín C; Ponte C; Soriano F; Coronel P; Gimeno M; Blanco J Int J Antimicrob Agents; 2006 Aug; 28(2):151-3. PubMed ID: 16815688 [No Abstract] [Full Text] [Related]
23. [In vitro effects of cefotetan on anaerobic bacteria of the genus Bacteroides fragilis group, in comparison with 8 antibiotics]. Trevisan R; Proietti A; Pitzus E G Ital Chemioter; 1985; 32(2):367-70. PubMed ID: 3869115 [No Abstract] [Full Text] [Related]
24. A comparison of cefotetan and cephazolin for prophylaxis against wound infection after elective cholecystectomy. Drumm J; Donovan IA; Wise R J Hosp Infect; 1985 Sep; 6(3):277-80. PubMed ID: 2865292 [TBL] [Abstract][Full Text] [Related]
25. In vitro bactericidal activities and morphologic changes in Escherichia coli and Bacteroides fragilis by cephalosporins. Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Satoh M; Kai J; Tamaya T Chemotherapy; 1998; 44(3):157-63. PubMed ID: 9612605 [TBL] [Abstract][Full Text] [Related]
26. Cefotetan versus clindamycin/tobramycin association in mixed aero-anaerobic peritonitis in rats. Nardone A; Nespoli A; Padalino P; Marradi C Chemioterapia; 1987 Jun; 6(2 Suppl):182-3. PubMed ID: 2475263 [No Abstract] [Full Text] [Related]
27. [In vitro effects of cefotetan against Bacteroides of the fragilis group]. Privitera G; Ortisi G; Rossi R; Vigo B G Ital Chemioter; 1985; 32(2):371-4. PubMed ID: 3869116 [No Abstract] [Full Text] [Related]
28. Effect of Bacteroides fragilis on mortality induced by Escherichia coli in an experimental infection treated with cefotaxime, aztreonam or gentamicin. Soriano F; Ponte C; Santamaría M; Castilla C J Antimicrob Chemother; 1989 Mar; 23(3):383-8. PubMed ID: 2659565 [TBL] [Abstract][Full Text] [Related]
29. In vivo antibacterial activity of cefodizime, a new cephalosporin antibiotic. Kasai K; Tsuji A; Miyazaki S; Goto S; Fujimoto K; Masuyoshi S; Arai S Jpn J Antibiot; 1984 Jul; 37(7):1306-12. PubMed ID: 6092740 [TBL] [Abstract][Full Text] [Related]
30. Formulary evaluation of second-generation cephamycin derivatives using decision analysis. Barriere SL Am J Hosp Pharm; 1991 Oct; 48(10):2146-50. PubMed ID: 1781469 [TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. Mikamo H; Izumi K; Hua YX; Hayasaki Y; Sato Y; Tamaya T J Antimicrob Chemother; 2000 Sep; 46(3):471-4. PubMed ID: 10980177 [TBL] [Abstract][Full Text] [Related]
32. Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem. Andrew JH; Greenwood D J Antimicrob Chemother; 1987 May; 19(5):591-5. PubMed ID: 3497146 [TBL] [Abstract][Full Text] [Related]
33. Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. Lami JL; Wilson SE; Hopkins JA Am Surg; 1991 Dec; 57(12):769-74. PubMed ID: 1746792 [TBL] [Abstract][Full Text] [Related]